Annovis Bio, Inc. (ANVS)
0.9934
-0.06
(-5.39%)
USD |
NYSE |
Oct 16, 16:00
1.00
+0.01
(+0.66%)
Pre-Market: 20:00
Annovis Bio Enterprise Value : 23.60M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 23.60M |
| October 15, 2026 | 26.01M |
| October 14, 2026 | 24.73M |
| October 13, 2026 | 26.43M |
| October 12, 2026 | 30.27M |
| October 09, 2026 | 32.82M |
| October 08, 2026 | 31.12M |
| October 07, 2026 | 32.82M |
| October 06, 2026 | 31.55M |
| October 05, 2026 | 32.40M |
| October 02, 2026 | 31.55M |
| October 01, 2026 | 31.12M |
| September 30, 2026 | 35.38M |
| September 29, 2026 | 36.66M |
| September 28, 2026 | 40.07M |
| September 25, 2026 | 37.09M |
| September 24, 2026 | 37.94M |
| September 23, 2026 | 35.38M |
| September 22, 2026 | 34.95M |
| September 21, 2026 | 31.97M |
| September 18, 2026 | 29.84M |
| September 17, 2026 | 28.14M |
| September 16, 2026 | 25.58M |
| September 15, 2026 | 28.99M |
| September 14, 2026 | 29.84M |
| Date | Value |
|---|---|
| September 11, 2026 | 28.99M |
| September 10, 2026 | 31.97M |
| September 09, 2026 | 33.25M |
| September 08, 2026 | 36.66M |
| September 04, 2026 | 40.49M |
| September 03, 2026 | 40.07M |
| September 02, 2026 | 53.70M |
| September 01, 2026 | 53.28M |
| August 31, 2026 | 54.55M |
| August 28, 2026 | 54.55M |
| August 27, 2026 | 58.39M |
| August 26, 2026 | 57.11M |
| August 25, 2026 | 58.81M |
| August 24, 2026 | 55.83M |
| August 21, 2026 | 58.81M |
| August 20, 2026 | 57.54M |
| August 19, 2026 | 60.09M |
| August 18, 2026 | 57.96M |
| August 17, 2026 | 55.41M |
| August 14, 2026 | 60.09M |
| August 13, 2026 | 57.54M |
| August 12, 2026 | 57.96M |
| August 11, 2026 | 61.80M |
| August 10, 2026 | 61.80M |
| August 07, 2026 | 61.37M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.409B |
| Alnylam Pharmaceuticals, Inc. | 30.68B |
| Anika Therapeutics, Inc. | 254.23M |
| Savara, Inc. | 771.40M |
| Vericel Corp. | 1.986B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.82M |
| Total Expenses (Quarterly) | 14.82M |
| EPS Diluted (Quarterly) | -0.395 |
| Earnings Yield | -180.4% |
| Normalized Earnings Yield | -182.20 |